Shanghai Vitalgen BioPharma Co., Ltd. and its wholly-owned subsidiary Vitalgen (Shenzhen) BioPharma Co., Ltd. (together referred to as the "Company") recently announced that the company's independently developed VGN-R08b has received Investigational New Drug (IND) clearance from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) to conduct clinical studies for the treatment of GBA1 mutation-associated Parkinson's disease (PD-GBA). This marks the company's second gene therapy product for Parkinson's disease (PD) to enter the clinical stage, following the 2024 IND clearances in both China and the U.S. for VGN-R09b, a gene therapy product for the treatment of idiopathic Parkinson's disease. With these approvals, Vitalgen has initially established a dual-track therapeutic strategy covering both idiopathic and genetic subtypes of Parkinson's disease.
GBA1 mutation-associated Parkinson's disease represents one of the most common genetic risk-related subtypes of Parkinson's disease. Compared to idiopathic PD, PD-GBA typically presents with earlier disease onset and more rapid disease progression. Heterozygous mutations in the GBA1 gene lead to lysosomal metabolic dysfunction, resulting in the abnormal accumulation of α-synuclein in the brain, which is a core pathological feature of Parkinson's disease. This well-characterized pathogenic mechanism not only provides a molecular biological basis for the clinical diagnosis of PD-GBA but also establishes the critical scientific foundation for precisely targeting this PD subtype with gene therapy.
In terms of therapeutic strategy, VGN-R08b is a recombinant AAV-based gene replacement therapy specifically designed to address GBA1 gene mutations. It aims to restore lysosomal function at its root by supplementing the functional gene, thereby slowing disease progression. In contrast, VGN-R09b targets idiopathic Parkinson's disease, focusing on functional reconstruction of the dopaminergic pathway and broad-spectrum neuroprotection. The two products are complementary in their mechanisms of action and target patient populations, collectively establishing the company's differentiated product portfolio in the PD field, which encompasses both "precision etiological targeting" and "broad-spectrum modulation." This demonstrates the company's continued commitment to advancing therapies in the field of neurological disorders.
Dr. Zhao Xiaoping, CEO of the company, stated: "The simultaneous IND clearances for VGN-R08b in China and the U.S. represent a significant advancement in our global research and development strategy. With both VGN-R09b and VGN-R08b now having entered the clinical stage, we have initially established a two-pronged Parkinson's disease pipeline driven by 'broad-spectrum' and 'precision' approaches. Moving forward, we will fully dedicate our efforts to advancing clinical studies, aiming to bring new therapeutic hope to patients with different subtypes of Parkinson's disease.
About VGN-R08b
VGN-R08b is a gene therapy product independently developed and manufactured by the company, utilizing a recombinant AAV vector. Administered via intracerebroventricular injection, it precisely delivers the functional GBA1 gene to patients' neurons and glial cells. This enables the cells to continuously produce functional GCase protein, which replaces the mutated endogenous GCase, degrades pathologically accumulated glucocerebrosides, thereby restoring neuronal function and alleviating central nervous system involvement. The product is designed to improve patients' disease symptoms at the etiological level.